251 related articles for article (PubMed ID: 31436563)
21. NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.
Toonen JA; Anastasaki C; Smithson LJ; Gianino SM; Li K; Kesterson RA; Gutmann DH
Hum Mol Genet; 2016 May; 25(9):1703-13. PubMed ID: 26908603
[TBL] [Abstract][Full Text] [Related]
22. A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations.
Sharif S; Upadhyaya M; Ferner R; Majounie E; Shenton A; Baser M; Thakker N; Evans DG
J Med Genet; 2011 Apr; 48(4):256-60. PubMed ID: 21278392
[TBL] [Abstract][Full Text] [Related]
23. Recent Advances in the Diagnosis and Pathogenesis of Neurofibromatosis Type 1 (NF1)-associated Peripheral Nervous System Neoplasms.
Longo JF; Weber SM; Turner-Ivey BP; Carroll SL
Adv Anat Pathol; 2018 Sep; 25(5):353-368. PubMed ID: 29762158
[TBL] [Abstract][Full Text] [Related]
24. Neurofibromatosis type 1 (NF1): diagnosis and management.
Ferner RE; Gutmann DH
Handb Clin Neurol; 2013; 115():939-55. PubMed ID: 23931823
[TBL] [Abstract][Full Text] [Related]
25. Neurofibromin in the brain.
Gutmann DH
J Child Neurol; 2002 Aug; 17(8):592-601; discussion 602-4, 646-51. PubMed ID: 12403558
[TBL] [Abstract][Full Text] [Related]
26. The activation of the WNT signaling pathway is a Hallmark in neurofibromatosis type 1 tumorigenesis.
Luscan A; Shackleford G; Masliah-Planchon J; Laurendeau I; Ortonne N; Varin J; Lallemand F; Leroy K; Dumaine V; Hivelin M; Borderie D; De Raedt T; Valeyrie-Allanore L; Larousserie F; Terris B; Lantieri L; Vidaud M; Vidaud D; Wolkenstein P; Parfait B; Bièche I; Massaad C; Pasmant E
Clin Cancer Res; 2014 Jan; 20(2):358-71. PubMed ID: 24218515
[TBL] [Abstract][Full Text] [Related]
27. Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours.
Bottillo I; Ahlquist T; Brekke H; Danielsen SA; van den Berg E; Mertens F; Lothe RA; Dallapiccola B
J Pathol; 2009 Apr; 217(5):693-701. PubMed ID: 19142971
[TBL] [Abstract][Full Text] [Related]
28. Dissecting Clinical Heterogeneity in Neurofibromatosis Type 1.
Monroe CL; Dahiya S; Gutmann DH
Annu Rev Pathol; 2017 Jan; 12():53-74. PubMed ID: 28135565
[TBL] [Abstract][Full Text] [Related]
29. The molecular landscape of glioma in patients with Neurofibromatosis 1.
D'Angelo F; Ceccarelli M; Tala ; Garofano L; Zhang J; Frattini V; Caruso FP; Lewis G; Alfaro KD; Bauchet L; Berzero G; Cachia D; Cangiano M; Capelle L; de Groot J; DiMeco F; Ducray F; Farah W; Finocchiaro G; Goutagny S; Kamiya-Matsuoka C; Lavarino C; Loiseau H; Lorgis V; Marras CE; McCutcheon I; Nam DH; Ronchi S; Saletti V; Seizeur R; Slopis J; Suñol M; Vandenbos F; Varlet P; Vidaud D; Watts C; Tabar V; Reuss DE; Kim SK; Meyronet D; Mokhtari K; Salvador H; Bhat KP; Eoli M; Sanson M; Lasorella A; Iavarone A
Nat Med; 2019 Jan; 25(1):176-187. PubMed ID: 30531922
[TBL] [Abstract][Full Text] [Related]
30. An Overview of Optic Pathway Glioma With Neurofibromatosis Type 1: Pathogenesis, Risk Factors, and Therapeutic Strategies.
Chen Y; Yu J; Ge S; Jia R; Song X; Wang Y; Fan X
Invest Ophthalmol Vis Sci; 2024 Jun; 65(6):8. PubMed ID: 38837168
[TBL] [Abstract][Full Text] [Related]
31. The heterogeneous nature of germline mutations in NF1 patients with malignant peripheral serve sheath tumours (MPNSTs).
Upadhyaya M; Spurlock G; Majounie E; Griffiths S; Forrester N; Baser M; Huson SM; Gareth Evans D; Ferner R
Hum Mutat; 2006 Jul; 27(7):716. PubMed ID: 16786508
[TBL] [Abstract][Full Text] [Related]
32. NF1 truncating mutations associated to aggressive clinical phenotype with elephantiasis neuromatosa and solid malignancies.
Ponti G; Martorana D; Pellacani G; Ruini C; Loschi P; Baccarani A; De Santis G; Pollio A; Neri TM; Mandel VD; Maiorana A; Maccio L; Maccaferri M; Tomasi A
Anticancer Res; 2014 Jun; 34(6):3021-30. PubMed ID: 24922668
[TBL] [Abstract][Full Text] [Related]
33. No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients.
Hutter S; Piro RM; Waszak SM; Kehrer-Sawatzki H; Friedrich RE; Lassaletta A; Witt O; Korbel JO; Lichter P; Schuhmann MU; Pfister SM; Tabori U; Mautner VF; Jones DTW
Hum Genet; 2016 May; 135(5):469-475. PubMed ID: 26969325
[TBL] [Abstract][Full Text] [Related]
34. Cutaneous neurofibromas in the genomics era: current understanding and open questions.
Allaway RJ; Gosline SJC; La Rosa S; Knight P; Bakker A; Guinney J; Le LQ
Br J Cancer; 2018 Jun; 118(12):1539-1548. PubMed ID: 29695767
[TBL] [Abstract][Full Text] [Related]
35. The impact of coexisting genetic mutations on murine optic glioma biology.
Kaul A; Toonen JA; Gianino SM; Gutmann DH
Neuro Oncol; 2015 May; 17(5):670-7. PubMed ID: 25246427
[TBL] [Abstract][Full Text] [Related]
36. Somatic neurofibromatosis type 1 (NF1) inactivation events in cutaneous neurofibromas of a single NF1 patient.
Emmerich D; Zemojtel T; Hecht J; Krawitz P; Spielmann M; Kühnisch J; Kobus K; Osswald M; Heinrich V; Berlien P; Müller U; Mautner VF; Wimmer K; Robinson PN; Vingron M; Tinschert S; Mundlos S; Kolanczyk M
Eur J Hum Genet; 2015 Jun; 23(6):870-3. PubMed ID: 25293717
[TBL] [Abstract][Full Text] [Related]
37. Association between benign and malignant peripheral nerve sheath tumors in NF1.
Tucker T; Wolkenstein P; Revuz J; Zeller J; Friedman JM
Neurology; 2005 Jul; 65(2):205-11. PubMed ID: 16043787
[TBL] [Abstract][Full Text] [Related]
38. Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation.
Daginakatte GC; Gianino SM; Zhao NW; Parsadanian AS; Gutmann DH
Cancer Res; 2008 Dec; 68(24):10358-66. PubMed ID: 19074905
[TBL] [Abstract][Full Text] [Related]
39. Neurofibromatosis type 1.
Boyd KP; Korf BR; Theos A
J Am Acad Dermatol; 2009 Jul; 61(1):1-14; quiz 15-6. PubMed ID: 19539839
[TBL] [Abstract][Full Text] [Related]
40. Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.
Zhu Y; Harada T; Liu L; Lush ME; Guignard F; Harada C; Burns DK; Bajenaru ML; Gutmann DH; Parada LF
Development; 2005 Dec; 132(24):5577-88. PubMed ID: 16314489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
